It was reported that on (b)(6) 2014, a 2.75x48mm xience xpedition was successfully implanted in the mildly tortuous, concentric, de novo, 90% stenosed, proximal right coronary artery.On (b)(6) 2014, the patient experienced angina with exertion and was hospitalized for a diagnostic coronary angiogram.75% in-stent restenosis was noted.No treatment was provided.No additional information was provided.
|
(b)(4).Concomitant products: stent: promus element plus; other: dual antiplatelet therapy (dapt).The stent remains in the vessel.It is indicated that the device is not returning for evaluation; therefore a failure analysis of the complaint device could not be completed.A review of the lot history record revealed no non-conformances that would have contributed to the reported event.Stenosis and angina are listed in the xience xpedition 48 everolimus eluting coronary stent systems instructions for use (ifu) as known patient effects of coronary stenting procedures.Although a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined, there is no indication of a product quality deficiency with respect to manufacturing, design or labeling.Based on the information reviewed, there is no evidence to indicate the presence of a product deficiency.The xience xpedition 48 is currently not commercially available in the u.S.A.; however, it is similar to a device sold in the u.S.A.
|